{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:39:42Z","timestamp":1781840382711,"version":"3.54.5"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000725","name":"The","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011440","name":"was","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007472","name":"UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007472","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000545","name":"British Association of Dermatologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000837","name":"University of Nottingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Pyoderma gangrenosum (PG) is an ulcerative inflammatory disorder affecting the lower legs in 80% of patients. The use of biologic medications to treat PG is increasing, although there is a limited evidence base to guide treatment choices. In some health systems, such as the UK National Health Service, limitations are placed on biologic prescribing for PG, leading to wide variations in prescribing. A survey of mainly UK clinicians showed that prednisolone remains the first-line treatment for PG (90%, 34\/38). Biologics have been used by 66% (25\/38) of clinicians as second-line therapy, but 19% (7\/38) have had prescribing requests declined. Further research is needed to determine optimal treatment strategies for PG.<\/jats:p>","DOI":"10.1093\/ced\/llae153","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T11:45:09Z","timestamp":1714045509000},"page":"1213-1216","source":"Crossref","is-referenced-by-count":1,"title":["Current prescribing for pyoderma gangrenosum in the UK and access to biologic medications: results from a UK Dermatology Clinical Trials Network survey of dermatologists"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0995-382X","authenticated-orcid":false,"given":"Myfanwy","family":"Jenkins","sequence":"first","affiliation":[{"name":"Department of Dermatology, Royal Victoria Infirmary , Newcastle upon Tyne , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Watson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Victoria Infirmary , Newcastle upon Tyne , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"McPhee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Nottingham , Nottingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3393-8305","authenticated-orcid":false,"given":"Nick J","family":"Levell","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Norfolk and Norwich University Hospital NHS Trust , Norwich , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1466-2016","authenticated-orcid":false,"given":"Mike","family":"Arden-Jones","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Southampton Faculty of Medicine , Southampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"D Ormerod","sequence":"additional","affiliation":[{"name":"University of Aberdeen , Aberdeen , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J","family":"Hampton","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Newcastle Upon Tyne Hospitals NHS Trust , Newcastle upon Tyne , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"2024091818145702200_llae153-B1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-023-01931-3","article-title":"Pyoderma gangrenosum: treatment options","volume":"83","author":"Dissemond","year":"2023","journal-title":"Drugs"},{"key":"2024091818145702200_llae153-B2","doi-asserted-by":"crossref","first-page":"h2958","DOI":"10.1136\/bmj.h2958","article-title":"Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial","volume":"350","author":"Ormerod","year":"2015","journal-title":"BMJ"},{"key":"2024091818145702200_llae153-B3","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1111\/1346-8138.16845","article-title":"Clinical guidance of pyoderma gangrenosum 2022","volume":"50","author":"Yamamoto","year":"2023","journal-title":"J Dermatol"},{"key":"2024091818145702200_llae153-B4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"2024091818145702200_llae153-B5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/iwj.13067","article-title":"Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi-systematic review","volume":"16","author":"Ben Abdallah","year":"2019","journal-title":"Int Wound J"},{"key":"2024091818145702200_llae153-B6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/1346-8138.16337","article-title":"Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: final analysis of a 52-week phase 3 open-label study","volume":"49","author":"Yamasaki","year":"2022","journal-title":"J Dermatol"},{"key":"2024091818145702200_llae153-B7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1159\/000519320","article-title":"Pyoderma gangrenosum and interleukin inhibitors: a semi-systematic review","volume":"238","author":"Ben Abdallah","year":"2022","journal-title":"Dermatology"},{"key":"2024091818145702200_llae153-B8","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1007\/s00403-023-02729-9","article-title":"Minimum data set for treatment effectiveness in pyoderma gangrenosum (MIDSTEP): an international protocol of an e-Delphi study to develop a clinical physician-driven treatment effectiveness registry on behalf of the UPGRADE initiative","volume":"315","author":"Haddadin","year":"2023","journal-title":"Arch Dermatol Res"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae153\/58463449\/llae153.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1213\/59183576\/llae153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1213\/59183576\/llae153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T18:15:10Z","timestamp":1726683310000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/10\/1213\/7657878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":8,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,4,25]]},"published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae153","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,4,25]]}}}